PMID- 35914435
OWN - NLM
STAT- MEDLINE
DCOM- 20220830
LR  - 20221101
IS  - 1525-5069 (Electronic)
IS  - 1525-5050 (Linking)
VI  - 134
DP  - 2022 Sep
TI  - Efficacy and safety of lacosamide in pediatric patients with epilepsy: A 
      systematic review and meta-analysis.
PG  - 108781
LID - S1525-5050(22)00230-X [pii]
LID - 10.1016/j.yebeh.2022.108781 [doi]
AB  - OBJECTIVE: Lacosamide (LCM), is a third-generation antiseizure medicine, with 
      limited clinical evidence for use in pediatric populations. We aimed to evaluate 
      evidence for the efficacy and safety of LCM in pediatric patients with epilepsy. 
      METHODS: A systematic review was performed using literature published from 
      inception to February 2022 identified in MEDLINE, Embase, Cochrane Library, and 
      four Chinese databases. Efficacy and safety outcome data were collected, and a 
      meta-analysis was performed. RESULT: Twenty-one studies involving 1230 pediatric 
      patients were included. The median percent reduction in seizure frequency per 
      28 days from baseline to maintenance was 33.1% (95% confidence interval [CI] 
      22.7%, 43.5%). After 6 months of treatment, the 50%, 75%, and 100% responder 
      rates were 53.3% (95% CI 40.7%, 65.9%), 28.3% (95% CI 20.8%, 35.8%), and 20.4% 
      (95% CI 12.6%, 28.2%), respectively. After 12 months of treatment, the 50%, 75%, 
      and 100% responder rates were 42.0% (95% CI 29.5%, 54.5%), 19.5% (95% CI 11.1%, 
      27.8%), and 15.2% (95% CI 6.6%, 23.8%), respectively. The most common adverse 
      events (AEs) were drowsiness (15.0%), dizziness (9.9%), and somnolence (8.3%). 
      CONCLUSION: Lacosamide is generally effective and well tolerated to use in 
      children with epilepsy. However, further research with high-quality data and 
      long-term follow-up of LCM use in pediatric populations is needed.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Yang, Chunsong
AU  - Yang C
AD  - Department of Pharmacy, Evidence-based Pharmacy Center, West China Second 
      Hospital, Sichuan University, China; Key Laboratory of Birth Defects and Related 
      Diseases of Women and Children (Sichuan University), Ministry of Education, 
      China.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Trauma Center Ward 2, West China Hospital, Sichuan University/West 
      China School of Nursing, Sichuan University, China.
FAU - Peng, Yuxuan
AU  - Peng Y
AD  - Department of Trauma Center Ward 2, West China Hospital, Sichuan University/West 
      China School of Nursing, Sichuan University, China.
FAU - Zhang, Lingli
AU  - Zhang L
AD  - Department of Pharmacy, Evidence-based Pharmacy Center, West China Second 
      Hospital, Sichuan University, China; Key Laboratory of Birth Defects and Related 
      Diseases of Women and Children (Sichuan University), Ministry of Education, 
      China. Electronic address: zhlingli@sina.com.
FAU - Yu, Dan
AU  - Yu D
AD  - Key Laboratory of Birth Defects and Related Diseases of Women and Children 
      (Sichuan University), Ministry of Education, China; Department of Children's 
      Genetic Endocrinology and Metabolism, China; West China School of Pharmacy, 
      Sichuan University, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20220729
PL  - United States
TA  - Epilepsy Behav
JT  - Epilepsy & behavior : E&B
JID - 100892858
RN  - 0 (Anticonvulsants)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Anticonvulsants
MH  - Child
MH  - *Epilepsies, Partial
MH  - *Epilepsy
MH  - Humans
MH  - Lacosamide
MH  - Sleepiness
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Efficacy
OT  - Lacosamide
OT  - Meta-analysis
OT  - Pediatric patients
OT  - Safety
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2022/08/02 06:00
MHDA- 2022/08/31 06:00
CRDT- 2022/08/01 18:21
PHST- 2022/03/13 00:00 [received]
PHST- 2022/05/16 00:00 [revised]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/08/02 06:00 [pubmed]
PHST- 2022/08/31 06:00 [medline]
PHST- 2022/08/01 18:21 [entrez]
AID - S1525-5050(22)00230-X [pii]
AID - 10.1016/j.yebeh.2022.108781 [doi]
PST - ppublish
SO  - Epilepsy Behav. 2022 Sep;134:108781. doi: 10.1016/j.yebeh.2022.108781. Epub 2022 
      Jul 29.